Stamford's Sema4 Named To List Of World’s Most Innovative Companies

STAMFORD, CT — Sema4, an AI-driven genomic and clinical data intelligence platform company that's based in Stamford, has been named to Fast Company's annual list of the World's Most Innovative Companies for 2022, according to a news release.

Sema4 was ranked as one of the top three most innovative companies in the Data Science category "for developing predictive tech for holistic health trajectories."

Microsoft was ranked No. 1 in the category, followed by Ipm.ai.

The full Data Science list can be found here.

"It is an honor that Fast Company has named Sema4 as one of the world’s most innovative companies," Dr. Eric Schadt said in a news release. Schadt is the founder and CEO of Sema4.

"This recognition showcases our commitment to utilizing artificial intelligence and machine learning to enable health systems in delivering precision medicine as the standard of care," he added. "It is also a tribute to our entire team at Sema4, which is driving forward highly innovative solutions to improve the quality of healthcare in ways that few people can yet imagine."

Fast Company recognized Sema4 for "closing the gap between the practice of medicine and the availability of more clinically actionable guidance, allowing for enhanced decision-making by physicians and patients to improve the prevention, management, and treatment of diseases," a news release on the announcement said.

Sema4’s data-driven approach to healthcare is powered by Centrellis, its innovative health intelligence platform. Centrellis is one of the largest and fastest growing integrated health information platforms in existence and provides data-driven insights to enable personalized medicine.

In 2021, the platform further expanded to include 12 million de-identified clinical records, more than 500,000 genomic profiles, and some of the most relevant life and biomedical science data in the digital universe.

Sema4 hopes that in the future, physicians and patients routinely query its platform of algorithms to help determine the most optimal health course journey, personalized to each individual.

The company also focuses on women's health, oncology and biopharma.

"The world’s most innovative companies play an essential role in addressing the most pressing issues facing society, whether they’re fighting climate change by spurring decarbonization efforts, ameliorating the strain on supply chains, or helping us reconnect with one another over shared passions," said Fast Company Deputy Editor David Lidsky in a news release.

The announcement comes after a year of growth for Sema4, which included appointing people to newly established positions, and expanding patient records by roughly 100 percent, the company said.

In the last year, the company was listed on the Nasdaq via a SPAC with CM Life Sciences. The listing brought in $500 million in cash onto the company's balance sheet, the company said.

Sema4 also secured three new health system partnerships with NorthShore University HealthSystem, AdventHealth, and Avera Health, expanding Sema4’s reach to an additional estimated 10 million patients.

In January, Sema4 announced a deal to acquire GeneDx, a genomic testing and analysis firm.

Over the past two years, Sema4 was one of largest providers of COVID-19 testing services in Connecticut. The services ended with the state earlier this year.

Fast Company’s Most Innovative Companies issue (March/April 2022) is available online here, as well as in-app form via iTunes, and on newsstands beginning March 15.

For more information on Sema4, visit their website.